A. Edgar Miller, William R. Levis
Citation Information: J Clin Invest. 1973;52(8):1925-1930. https://doi.org/10.1172/JCI107376.
A. Edgar Miller, William R. Levis
Published August 1, 1973
Citation Information: J Clin Invest. 1973;52(8):1925-1930. https://doi.org/10.1172/JCI107376.
Abstract
An evaluation of cell-mediated immunity in man is described that combines the advantages of an in vitro technique, lymphocyte transformation, with the use of contact sensitization to a primary immunogen, dinitrochlorobenzene (DNCB). DNCB, when coupled to autologous or allogeneic peripheral blood leukocytes, forms a complex, DNCB-antigen, that induces lymphocyte transformation specifically in leukocyte cultures from subjects sensitized to DNCB. Sequential studies of lymphocyte transformation to DNCB-antigen show that specifically reactive lymphocytes are first detected at about 10 days after in vivo application of a sensitizing dose of DNCB and reach a peak at about 14-21 days.
Authors
A. Edgar Miller, William R. Levis
Full Text PDF | Download (974.16 KB)
Copyright © 2024 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)